当前位置: X-MOL 学术Ann. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide
Annals of Oncology ( IF 56.7 ) Pub Date : 2017-06-15 , DOI: 10.1093/annonc/mdx283
D.E. Rathkopf , M.R. Smith , C.J. Ryan , W.R. Berry , N.D. Shore , G. Liu , C.S. Higano , J.J. Alumkal , R. Hauke , R.F. Tutrone , M. Saleh , E. Chow Maneval , S. Thomas , D.S. Ricci , M.K. Yu , C.J. de Boer , A. Trinh , T. Kheoh , R. Bandekar , H.I. Scher , E.S. Antonarakis

Mutations in the androgen receptor (AR) ligand-binding domain (LBD), such as F877L and T878A, have been associated with resistance to next-generation AR-directed therapies. ARN-509-001 was a phase I/II study that evaluated apalutamide activity in castration-resistant prostate cancer (CRPC). Here, we evaluated the type and frequency of 11 relevant AR-LBD mutations in apalutamide-treated CRPC patients.

中文翻译:

阿帕鲁胺治疗去势抵抗性前列腺癌患者的雄激素受体突变

雄激素受体(AR)配体结合域(LBD)中的突变,例如F877L和T878A,已与对下一代AR导向疗法的耐药性相关。ARN-509-001是一项I / II期研究,评估了去势抵抗性前列腺癌(CRPC)中阿帕鲁胺的活性。在这里,我们评估了阿帕鲁胺治疗的CRPC患者中11种相关AR-LBD突变的类型和频率。
更新日期:2017-09-18
down
wechat
bug